Loading...
XSHE
002424
Market cap979mUSD
Sep 30, Last price  
4.69CNY
Name

Guizhou Bailing Group Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHE:002424 chart
P/E
—
P/S
2.15
EPS
—
Div yield, %
—
Shrs. gr., 5y
-2.51%
Rev. gr., 5y
-0.41%
Revenues
3.05b
-20.31%
601,489,227727,281,988863,756,4491,138,426,6791,367,582,4471,405,330,3301,574,672,1621,899,087,6182,214,211,0732,591,816,6493,136,843,2312,850,585,2493,087,888,2003,111,649,5473,111,123,8273,540,132,2723,540,132,2724,262,971,4393,825,384,5683,048,628,245
Net income
-104m
L
80,295,567111,666,857158,198,365208,381,046221,752,176269,604,481310,477,909411,374,648482,327,101526,137,365563,238,893282,748,969152,375,362118,482,584118,482,589138,473,917138,473,918-414,511,22033,621,934-104,366,037
CFO
749m
+8,200.07%
00125,307,7330201,903,32219,516,226141,756,275395,833,192413,228,742466,615,47979,884,2490467,413,827231,779,655324,922,220502,152,213125,767,0589,020,627748,718,522
Dividend
May 29, 20200.22 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating within China, Guizhou Bailing Group Pharmaceutical Co., Ltd. specializes in the full spectrum of activities for traditional Chinese medicine, from initial research and development to manufacturing and market distribution. The company provides a diverse portfolio of medicinal preparations, available in numerous forms including tablets, capsules, granules, liquid syrups, pills, powdered formulations, tinctures, sprays, and topical ointments. These remedies are formulated to address a wide range of health concerns, such as cardiovascular and cerebrovascular conditions, common respiratory issues like coughs and colds, and specific pediatric and gynecological disorders. Established in 2005, its primary operational base is situated in Anshun, China.

Key people

Hongxing Li
Chief Financial Officer · since 2020
Jixian Feng
Deputy General Manager · since 2021
Yuanzhen Yuan
Executive Deputy General Manager · since 2022
Maoxue Zheng
Deputy General Manager · since 2021
Wei Jiang
Chairman of the Board, Acting Secretary of the Board · since 2024
Pei Chen
Deputy General Manager, Director · since 2024
Yong Jiang
Director · since 2021
Yifeng Zhou
Director · since 2022
Jian Hu
Independent Director · since 2020
Guowan Yan
Independent Director · since 2023
Ming Yang
Independent Director · since 2023
Hongwu Zhang
Independent Director · since 2023
IPO date
Jun 03, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT